{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "INT-7",
        "affectedSection": "Section 1.6, 1.7",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated safety profile to include cerebrovascular accidents and aligned with current Investigator's Brochure."
      },
      {
        "id": "impact_2",
        "amendmentId": "INT-7",
        "affectedSection": "Table 1, Section 9.5",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Increased frequency of vital sign monitoring (pulse and blood pressure) at every visit."
      },
      {
        "id": "impact_3",
        "amendmentId": "INT-6",
        "affectedSection": "Section 9.4.1, Table 1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Halted collection of MRD samples for subjects already in Complete Response."
      },
      {
        "id": "impact_4",
        "amendmentId": "INT-5",
        "affectedSection": "Section 6.4.3.1, Attachment 8",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added specific dose modification guidelines for subjects with chronic hepatic impairment based on Child-Pugh scores."
      },
      {
        "id": "impact_5",
        "amendmentId": "INT-4",
        "affectedSection": "Section 11.8, Synopsis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added a second interim analysis at 180 PFS events and adjusted alpha spending."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "INT-7",
        "reasonText": "To align with the ibrutinib Investigatorâ€™s Brochure regarding new safety observations of cerebrovascular accidents.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "INT-6",
        "reasonText": "Stopping collection for current CR subjects has no impact on MRD-negative rate endpoint as samples are already secured.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "INT-5",
        "reasonText": "To allow DMC recommendations for treatment unblinding or stopping placebo following interim analysis results.",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "INT-4",
        "reasonText": "Mitigate potential long interval between first interim and final analysis due to lower than expected event rate.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "INT-7",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.6, 1.7",
        "beforeText": "Previous safety data",
        "afterText": "Updated safety information including cerebrovascular accidents from post-marketing setting",
        "summary": "Safety update to align with Investigator's Brochure."
      },
      {
        "id": "change_2",
        "amendmentId": "INT-2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "12.3.3.1",
        "beforeText": "Any hemorrhagic event that is Grade 3 or greater in severity or results in loss of vision, transfusion, or hospitalization.",
        "afterText": "Any Grade 3+ hemorrhagic event; any serious bleeding event of any grade; any CNS hemorrhage/hematoma of any grade.",
        "summary": "Broadened the definition of Major Hemorrhage."
      },
      {
        "id": "change_3",
        "amendmentId": "INT-2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1",
        "beforeText": "Hematology values must be within limits within 14 days prior to randomization",
        "afterText": "Hematology values must be within the following limits:",
        "summary": "Removed the specific 14-day timeframe for screening laboratory parameters."
      },
      {
        "id": "change_4",
        "amendmentId": "INT-2",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.3",
        "beforeText": "Not specified",
        "afterText": "If a dose is missed, it can be taken as soon as possible on the same day with a return to normal schedule the next day.",
        "summary": "Updated missed dose instructions for consistency with product label."
      },
      {
        "id": "change_5",
        "amendmentId": "INT-5",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.4.3.1",
        "beforeText": "null",
        "afterText": "Added instructions for dose modification of ibrutinib/placebo in subjects with chronic hepatic impairment based on Child-Pugh class A, B, or C.",
        "summary": "New hepatic impairment dosing guidelines."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}